Payment overview · 2025
General Payments
$490.49
18 reported records · 13 companies
Healthcare provider profile · identity verified
Clement Elechi, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SALEM, VA · NPI 1538146915
Verified facts
What the public records show
CMS Open Payments records show Clement Elechi, M.D. received $490.49 in general payments during 2025 across 18 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ubrelvy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vumerity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Nurtec Odt by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $90.16 | 18.4% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $85.44 | 17.4% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $57.62 | 11.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.39 | 7.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.86 | 6.9% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.72 | 6.5% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $26.98 | 5.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.83 | 5.3% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $25.12 | 5.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.30 | 4.5% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.84 | 3.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.67 | 3.8% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $16.56 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $417.99 | 17 |
| Education | $72.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $85.44 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $57.62 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $33.86 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $31.72 | 1 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $17.66 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $16.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 51 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 314 | 67 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 257 | 62 |
| Levetiracetam | Levetiracetam | 243 | 53 |
| Topiramate | Topiramate | 196 | 53 |
| Lamotrigine | Lamotrigine | 153 | 24 |
| Donepezil Hcl | Donepezil Hcl | 130 | 34 |
| Primidone | Primidone | 105 | 26 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 102 | 17 |
| Baclofen | Baclofen | 99 | 28 |
| Clonazepam | Clonazepam | 96 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 92 | 15 |
| Memantine Hcl | Memantine Hcl | 90 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 24 |
| Promethazine Hcl | Promethazine Hcl | 70 | suppressed |
| Pregabalin | Pregabalin | 68 | 19 |
| Divalproex Sodium | Divalproex Sodium | 63 | 18 |
| Methylphenidate Hcl | Methylphenidate Hcl | 63 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 62 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 13 |
| Alprazolam | Alprazolam | 55 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 13 |
| Zonisamide | Zonisamide | 52 | 15 |
| Nurtec Odt | Rimegepant Sulfate | 51 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | 12 |
| Aimovig Autoinjector | Erenumab-Aooe | 50 | suppressed |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 50 | 11 |
| Dimethyl Fumarate | Dimethyl Fumarate | 49 | suppressed |
| Prednisone | Prednisone | 49 | 16 |
| Ubrelvy | Ubrogepant | 49 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 48 | suppressed |
| Diazepam | Diazepam | 47 | 16 |
| Propranolol Hcl | Propranolol Hcl | 47 | 12 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 47 | 12 |
| Trazodone Hcl | Trazodone Hcl | 47 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 14 |
| Modafinil | Modafinil | 44 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 41 | suppressed |
| Teriflunomide | Teriflunomide | 41 | suppressed |
| Amantadine | Amantadine Hcl | 36 | suppressed |
| Lorazepam | Lorazepam | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Carbamazepine | Carbamazepine | 32 | suppressed |
| Lacosamide | Lacosamide | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 32 | suppressed |
| Qulipta | Atogepant | 32 | suppressed |
| Risperidone | Risperidone | 32 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Austedo | Deutetrabenazine | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Glatopa | Glatiramer Acetate | 26 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 26 | suppressed |
| Tecfidera | Dimethyl Fumarate | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Indomethacin | Indomethacin | 25 | suppressed |
| Acetazolamide | Acetazolamide | 24 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 24 | suppressed |
| Lamotrigine Er | Lamotrigine | 23 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 20 | suppressed |
| Armodafinil | Armodafinil | 19 | suppressed |
| Betaseron | Interferon Beta-1b | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 17 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 14 | suppressed |
| Lamictal | Lamotrigine | 14 | suppressed |
| Plegridy Pen | Peginterferon Beta-1a | 14 | suppressed |
| Vumerity | Diroximel Fumarate | 14 | suppressed |
| Kesimpta Pen | Ofatumumab | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $490.49 · 18 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, INGREZZA, KESIMPTA, NURTEC ODT, Ocrevus Zunovo, PURIFIED CORTROPHIN GEL, QULIPTA, Rystiggo, Sunosi, TYSABRI, UBRELVY, ULTOMIRIS, WAKIX, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error